Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:38:19.682Z.
Calculation as of: 2026-10-06T22:38:19.682Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$14.94M
PS Ratio
N/A
TTM Avg
1527.75
3Y Avg
1527.75
5Y Avg
1527.75
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | 10.04 | 7.29 | 6.12 | 1270.11 |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | 111.45 | 20.09 | 7.30 | 5.50 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | 0.10 | 0.76 | 0.68 | 1.36 |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | 107.03 | 130.06 | 643.92 | 552.45 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | 1.86 | 3.04 | 3.04 | 3.04 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A | 1527.75 | 1527.75 | 1527.75 |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
Half-year reporter: no trailing two-half-year basis, because the half-year figures do not reconcile with the annual report: the newest completed fiscal year's two halves differ from its annual revenue or net income by more than 5%.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
